secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001140361-23-053099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q3 net loss $10.8M; highlights 74% 2-year OS in VERSATILE-002 trial
-------------------------------------------------------------------------------

- Net loss of $10.8M ($0.35/share) vs $7.4M loss in Q3 2022; R&D expenses rose to $6.4M from $4.4M.
- Cash $54.3M at Sept 30, expected to fund operations into Q3 2024; VERSATILE-003 Phase 3 initiation planned Q1 2024.
- VERSATILE-002 interim: 24-month overall survival rate of 74% in ICI-naïve HPV+ head & neck cancer patients.
- NCI triple combo: 75% of ICI-naïve HPV+ cancer patients alive at 36 months; median OS not reached.
- PDS01ADC+docetaxel: PSA decreased in all 18 prostate cancer patients; 61% had ≥60% PSA decline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/0001140361-23-053099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/ef20014629_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-053099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer